COMMUNIQUÉS West-GlobeNewswire

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
27/02/2025
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. 27, 2025 (GLOBE [...]
ICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance
27/02/2025
SAN CLEMENTE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the [...]
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
27/02/2025
Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming months Enrollment completed in Qilu’s Phase 2 trial evaluating certepetide for the [...]
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results
27/02/2025
PONTE VEDRA, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results
27/02/2025
CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]
Clover Health Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance
27/02/2025
Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well [...]
Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results
27/02/2025
Total revenue of $59.3 million for the fiscal year ended December 31, 2024 Expect double digit growth for total revenue in 2025 2025 to demonstrate acceleration of commercial growth through double-stranded RNA ligase [...]
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
27/02/2025
DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
27/02/2025
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline [...]
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
27/02/2025
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a [...]
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
27/02/2025
Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key Stakeholder Engagement Efforts Expecting to Initiate Four Late-Stage Trials and [...]
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results
27/02/2025
— Record revenues of $701 million in 2024 — — Full-year GAAP net loss of $100 million and adjusted EBITDA of $224 million — — Conference call today at 4:30 p.m. ET — PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- [...]
Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook
27/02/2025
Validated technology with exceptional growth of customer publications and enhanced access to the Proteograph Product Suite with growing demand for Seer Technology Access Center (STAC) REDWOOD CITY, Calif., Feb. 27, 2025 [...]
Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook
27/02/2025
FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth [...]
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress
27/02/2025
Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors in H2 VTX3232 [...]
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
27/02/2025
Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)- [...]
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024
27/02/2025
Reshaping its Board of Directors at the upcoming Shareholders’ meeting with the aim of enhancing U.S. outreach Preparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in Borderline [...]
NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award
27/02/2025
TORONTO and HAIFA, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that it has been selected to present at [...]
Progyny, Inc. Announces Fourth Quarter 2024 Results
27/02/2025
Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% Growth Generated $52.2 Million of Quarterly Operating Cash Flow Issues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW [...]

Pages